QoL data support use of ultra-hypofractionated radiotherapy in prostate cancer
January 12th 2021Among patients with 6 years’ follow-up, no differences were observed between ultra-hypofractionation and conventional fractionation in the rates of clinically relevant deterioration in overall urinary bother, overall bowel bother, overall sexual bother, or global health/QoL.
Novel IL-15 superagonist complex highly active in BCG-unresponsive NMIBC
December 21st 2020Combining the novel interleukin-15 superagonist complex N-803 (Anktiva) with BCG led to a high complete response rate in patients with BCG-unresponsive, high-risk, non-muscle invasive bladder cancer with carcinoma in situ.